Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1006 - Effect On Oxaliplatin-Free Interval For Successful Rechallenge Of Oxaliplatin In Colorectal Cancer Patients Who Had Experienced An Oxaliplatin–Related Hypersensitivity Reaction.

Date

24 Nov 2018

Session

Poster display - Cocktail

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Satoshi Horasawa

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

S. Horasawa1, A. Kaneko2, D. Kotani1, S. Nakashima2, H. Bando1, T. Yoshino1

Author affiliations

  • 1 Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Pharmacy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 1006

Background

Oxaliplatin (Ox) is a key drug in patients (pts) with colorectal cancer (CRC). However, Ox causes a hypersensitivity reaction (HSR) in 15-20% of pts, leading to its discontinuation. There were few reports regarding effect on Ox-free interval for successful Ox rechallenge.

Methods

We retrospectively reviewed medical records of consecutive CRC pts who had received an Ox-containing regimen from 2005 to 2016 at our institution. The aim of this study was to investigate effect on Ox-free interval from the onset of the initial Ox-related HSR for successful Ox rechallenge under high-dose dexamethasone (HD-DEX) as premedication which comprise of intravenous DEX of 19.8 mg, chlorpheniramine of 5 mg, and famotidine of 20mg. The success of Ox rechallenge was defined as completion of at least one Ox administration without any HSR.

Results

1,343 pts who had received Ox containing regimens, and HSR occurred in 297 pts (22%). 188 pts who received a further Ox under the HD- DEX premedication were evaluable in this study, excluding 109 pts (70 pts discontinued Ox thereafter and 39 pts received a further Ox without using the HD-DEX). Among the 188 pts, pts with biweekly and tri-weekly Ox administration were 176 (94%) and 12 (6%), respectively. 92 pts (49%) developed a HSR recurrence and the grade 1/2/3 HSR by CTCAE v4.0 occurred in 37/54/1 pts, respectively. No HSR-related death was observed. Median and mean Ox-free intervals were 14 and 55 days, respectively (range, 13- 2,071 days). The 17 pts who had ≥ 55 days of Ox-free interval succeeded Ox rechallenge. In univariate and multivariate analyses, a longer Ox-free interval ≥ 30 days was significantly associated with a lower risk of HSR recurrence (Cutoff value=14 days, Odds Ratio [OR] =0.55, 95% CI: 0.26-1.14, p = 0.11: Cutoff=20 days, OR = 0.48, 95% CI: 0.21-1.08, p = 0.08: Cutoff=30 days, OR = 0.20, 95% CI: 0.05-0.93, p = 0.04: Cutoff=40 days, OR = 0.11, 95% CI: 0.02-0.89, p = 0.04).

Conclusions

This study suggests a longer Ox-free interval ≥ 30 days from the initial HSR may contribute to successful Ox rechallenge in CRC pts who had experienced an Ox–related HSR.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital East.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.